Octreotide and hepatocellular carcinoma.
Farinati
F
F
Sergio
A
A
Baldan
A
A
Zucchetta
P
P
Corleto
V D
VD
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D015282:Octreotide / Q000009:adverse effects / Q000627:therapeutic use*; D017481:Receptors, Somatostatin / Q000037:antagonists & inhibitors / Q000378:metabolism
D018931:Antineoplastic Agents, Hormonal; D017481:Receptors, Somatostatin; D015282:Octreotide